Dr. Richard H. Roe, MD

Dr. Roe practices at Retina-Vitreous Associates Medical Group in Los Angeles, California.

Dr. Roe's NPI, 1043412489, was assigned on June 5, 2007. Dr. Roe graduated from Sidney Kimmel Medical College in 2002. Dr. Roe's California license number on file is A95880.

Dr. Roe's primary practice is Retina-Vitreous Associates Medical Group, at 1245 W Wilshire Blvd, Los Angeles, CA 90017 in Los Angeles County. The practice phone is (213) 483-8810.

Dr. Roe's primary practice is Retina-Vitreous Associates Medical Group in Los Angeles, California. Dr. Roe is also affiliated with PIH Health Good Samaritan Hospital. The medical group on file is Harbor-UCLA Medical Center. Dmand AI also links Dr. Roe to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Roe practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Roe's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Roe is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Roe's licenses on file in 2 states: California and New York.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eye infection or inflammation, glaucoma, hypertensive retinopathy and inflammation of iris among the conditions Dr. Roe treats.

CMS data shows 21,330 Medicare services from Dr. Roe across 16 procedure codes in 2024, for 877 Medicare patients. Medicare paid $1,517,704 for them.

CMS counts 877 Medicare patients who saw Dr. Roe in 2024. The largest group is 65 to 74, with 310 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 51% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Roe's median patient age at 68, with 50% women.

In 2024, Dr. Roe wrote 968 Medicare Part D claims for 237 patients. 56% of them were for generic drugs. CMS names the drug for 885 of them, across 16 drugs with 11 or more claims each, at $94,271 in total drug cost. In 2023, CMS named 988 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Roe for performance year 2024, reported as part of a group. Dr. Roe accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 2 papers to Dr. Roe in 2016. Dr. Roe's most frequent co-authors are Michelle Valerie Carle, FRCSC, MD and Roger L. Novack, MD.

Dmand AI links Dr. Roe to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Macular Degeneration and Retinal Degeneration.

CMS Open Payments shows 214 general payments to Dr. Roe from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 52% of the total. Alcon Laboratories Inc paid the most, $24,211.

Dmand AI lists 1 award for Dr. Roe, most recently CMS Stage 1 EHR in 2012.

Dr. Roe graduated from Sidney Kimmel Medical College in 2002.

Dr. Roe is in network with 18 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.